Joseph Holmes Sells 385 Shares of Thermo Fisher Scientific (NYSE:TMO) Stock

Key Points

• Joseph Holmes, the Chief Accounting Officer of Thermo Fisher Scientific, sold 385 shares of the stock at an average price of $492.63, totaling approximately $189,662.55, resulting in a 14.24% decrease in his holdings.
• Thermo Fisher reported an earnings per share (EPS) of $5.36 for the last quarter, exceeding analysts' expectations of $5.22, with a revenue of $10.86 billion that also surpassed forecasts.
• The company will pay a quarterly dividend of $0.43 on October 15th, with a current annualized dividend yield of 0.4% and a dividend payout ratio of 9.95%.

Thermo Fisher Scientific Inc. (NYSE:TMO - Get Free Report) CAO Joseph Holmes sold 385 shares of the stock in a transaction dated Friday, August 29th. The stock was sold at an average price of $492.63, for a total transaction of $189,662.55. Following the completion of the sale, the chief accounting officer directly owned 2,319 shares in the company, valued at approximately $1,142,408.97. This trade represents a 14.24% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website.

Thermo Fisher Scientific Stock Performance

Shares of TMO stock traded down $5.90 during trading hours on Tuesday, reaching $486.82. The stock had a trading volume of 1,298,035 shares, compared to its average volume of 2,440,435. The firm has a market capitalization of $183.83 billion, a PE ratio of 28.16, a price-to-earnings-growth ratio of 2.63 and a beta of 0.75. The company has a debt-to-equity ratio of 0.65, a current ratio of 1.93 and a quick ratio of 1.50. The firm has a 50-day simple moving average of $454.36 and a 200-day simple moving average of $453.50. Thermo Fisher Scientific Inc. has a twelve month low of $385.46 and a twelve month high of $627.88.

Thermo Fisher Scientific (NYSE:TMO - Get Free Report) last released its earnings results on Wednesday, July 23rd. The medical research company reported $5.36 EPS for the quarter, beating the consensus estimate of $5.22 by $0.14. The firm had revenue of $10.86 billion for the quarter, compared to analysts' expectations of $10.68 billion. Thermo Fisher Scientific had a net margin of 15.24% and a return on equity of 16.82%. Thermo Fisher Scientific's quarterly revenue was up 2.9% on a year-over-year basis. During the same quarter last year, the company earned $5.37 EPS. Thermo Fisher Scientific has set its Q3 2025 guidance at 5.460-5.510 EPS. FY 2025 guidance at 22.220-22.840 EPS. As a group, equities analysts forecast that Thermo Fisher Scientific Inc. will post 23.28 earnings per share for the current year.

Thermo Fisher Scientific Dividend Announcement

The company also recently announced a quarterly dividend, which will be paid on Wednesday, October 15th. Shareholders of record on Monday, September 15th will be issued a $0.43 dividend. This represents a $1.72 annualized dividend and a dividend yield of 0.4%. The ex-dividend date is Monday, September 15th. Thermo Fisher Scientific's dividend payout ratio (DPR) is presently 9.95%.

Hedge Funds Weigh In On Thermo Fisher Scientific

A number of institutional investors have recently modified their holdings of the company. Centaurus Financial Inc. raised its position in shares of Thermo Fisher Scientific by 8.0% in the second quarter. Centaurus Financial Inc. now owns 7,176 shares of the medical research company's stock valued at $2,910,000 after purchasing an additional 534 shares during the period. MASTERINVEST Kapitalanlage GmbH bought a new position in Thermo Fisher Scientific during the second quarter worth $1,148,000. Stance Capital LLC bought a new position in Thermo Fisher Scientific during the second quarter worth $1,309,000. Pathway Financial Advisers LLC increased its position in Thermo Fisher Scientific by 7.7% during the second quarter. Pathway Financial Advisers LLC now owns 1,492 shares of the medical research company's stock worth $605,000 after acquiring an additional 107 shares during the period. Finally, North Dallas Bank & Trust Co. bought a new position in Thermo Fisher Scientific during the second quarter worth $437,000. Institutional investors own 89.23% of the company's stock.

Wall Street Analysts Forecast Growth

TMO has been the subject of several recent analyst reports. Evercore ISI decreased their target price on shares of Thermo Fisher Scientific from $500.00 to $480.00 and set an "outperform" rating for the company in a report on Tuesday, July 8th. Scotiabank upgraded shares of Thermo Fisher Scientific from a "sector perform" rating to a "sector outperform" rating and set a $590.00 target price for the company in a report on Friday, July 11th. Hsbc Global Res cut shares of Thermo Fisher Scientific from a "strong-buy" rating to a "hold" rating in a report on Thursday, July 24th. Wells Fargo & Company decreased their price target on shares of Thermo Fisher Scientific from $570.00 to $565.00 and set an "overweight" rating for the company in a report on Thursday, July 24th. Finally, William Blair started coverage on shares of Thermo Fisher Scientific in a report on Monday, August 18th. They set an "outperform" rating for the company. Sixteen research analysts have rated the stock with a Buy rating and six have issued a Hold rating to the company. According to data from MarketBeat.com, the company has a consensus rating of "Moderate Buy" and an average target price of $593.00.

Thermo Fisher Scientific Company Profile

Thermo Fisher Scientific Inc provides life sciences solutions, analytical instruments, specialty diagnostics, and laboratory products and biopharma services in the North America, Europe, Asia-Pacific, and internationally. The company's Life Sciences Solutions segment offers reagents, instruments, and consumables for biological and medical research, discovery, and production of drugs and vaccines, as well as diagnosis of infections and diseases; and solutions include biosciences, genetic sciences, and bio production to pharmaceutical, biotechnology, agricultural, clinical, healthcare, academic, and government markets.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.